Authors:
Kiran Puldinidi, Kunal Ahuja
Download free PDF
C4 Rice Engineering Market Size & Share 2026-2035
Report ID: GMI16254
|
Published Date: July 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Download Free PDF
Explore Our Licensing Options:
Immediate Delivery Available
Jump to Content
Market Size
Market Trends
Market Analysis
Market Share
Market Companies
Industry News
Table of Contents
Frequently Asked Questions
Research Methodology
Related Reports
Download Free PDF
C4 Rice Engineering Market
Get a free sample of this report
Get a free sample of this report C4 Rice Engineering Market
Is your requirement urgent? Please give us your business email
for a speedy delivery!
C4 Rice Engineering Market Size
The global market size of C4 rice engineering stood at USD 20.6 million in 2025, characterized by consistent spending within international research consortia, national agricultural efforts, and a relatively smaller yet growing share from the private sector. The market size is estimated to be USD 54.8 million by 2035, witnessing a growth of 10.1% CAGR over the 2026-2035 forecast period, as per the latest report by Global Market Insights Inc.
C4 Rice Engineering Market Key Takeaways
Market Leader: Integrated DNA Technologies (IDT) led with over 4.5% market share in 2025.
Leading Players: Top 5 players in this market include Integrated DNA Technologies (IDT), GenScript Biotech, Twist Bioscience, Cibus Inc., Tropic Biosciences, which collectively held a market share of 17.3% in 2025.
The underlying growth trend depicts the structural increase in the funding for photosynthesis engineering due to the synergy of factors such as food security, climate change adaptation, and advancements in technologies like gene editing and synthetic biology which shorten prototype creation timeframes.[1]Food and Agriculture Organization of the United Nations, https://www.fao.org The rising mismatch between rising population-driven rice demand and the yield limit achievable via traditional green revolution breeding approaches is contributing to the growing pressure on stakeholders regarding the need for C4 pathway engineering solutions.
Key Drivers
Drivers Impact Analysis
Driver
(~) % Impact on CAGR Forecast
Geographic Relevance
Impact Timeline
Plateauing green revolution yields / food security pressure
+3.5%
Global most acute in South Asia and Sub-Saharan Africa
Long term (≥ 4 years)
Sustained philanthropic and government funding
+2.5%
Asia Pacific, Europe, North America
Short term (≤ 2 years)
CRISPR and synthetic biology advances
+2.8%
North America, Europe, Asia Pacific
Medium term (2–4 years)
Plateauing Green Revolution Yield Gains and Structural Food Security Pressure
Standard approaches to breeding cereals have reached their natural biophysical limit when it comes to such staples as rice. It is estimated that global food output needs to rise by about 70% during the period from 2005/07 through 2050 to be able to provide food security for a population of 9.1 billion people. Rice, being the staple food for more than 50% of world population and delivering 20% of world's dietary energy, is in the focus of attention of food security specialists. According to the forecasts, global consumption of rice will hit 511 million tons by 2050, which would be 18% increase compared to 2010; rice consumption in Africa is forecasted to increase twofold over the period.[2]CGIAR, https://www.cgiar.org The inability of agricultural optimization to cope with increased demands has elevated the C4 photosynthesis engineering project to the strategic level and made it one of the key research priorities for the globe as, theoretically, the C4 engineered rice may be 50% more efficient in radiation use.[3]PubMed Central National Institutes of Health, https://pmc.ncbi.nlm.nih.gov
Sustained and Growing Philanthropic and Government Funding Commitments
Since 2008, the Bill & Melinda Gates Foundation has served as the main funding pillar behind organized efforts to engineer C4 rice, having provided IRRI with an initial grant of USD 11 million over three years towards the first phase of research.[4]International Rice Research Institute, https://www.irri.org Phase II attracted funding worth USD 14 million over three years from the Gates Foundation, the United Kingdom government, and IRRI. Phase III was funded by a grant worth USD 15 million through the University of Oxford while Phase IV has been ongoing from 2019 to 2024, but was recently extended till mid-2026.[5]C4 Rice Project, https://c4rice.com Alongside philanthropic funding, the EU Horizon research funding scheme, the UK's FCDO, and the research budgets of various governments in the Philippines, Australia, Taiwan, South Korea, and India have been providing institutional spending. Such diversified funding greatly protects the C4 rice engineering market from donor dependency and creates a minimum spending level for the base-case growth scenario.
Advances in CRISPR-Cas9 and Synthetic Biology Reducing R&D Timelines
The technology that is currently available to support the engineering of C4 rice has developed quite significantly from the time when this project began. The emergence of Golden Gate and MoClo cloning technology, combined with the dTALE/STAP synthetic transcription factor and promoter system, which was validated in 2022, allows cell-type specific and multi-gene expression on a scale never before seen before. One of the most remarkable accomplishments that took place in 2021 was installing all five core C4 photosynthetic genes within one construct in rice – an effort that would have taken about six years through conventional methods.
Key Challenges
Restraints Impact Analysis
Challenge
(~) % Impact on CAGR Forecast
Geographic Relevance
Impact Timeline
Long R&D timelines and prototype complexity
-2.5%
Global
Long term (≥ 4 years)
Multi-gene stacking / bundle sheath promoter scarcity
-1.8%
Asia Pacific, North America, Europe
Medium term (2–4 years)
GMO regulatory hurdles in target deployment markets
-2.0%
Asia Pacific, MEA, Latin America
Short term (≤ 2 years)
Long R&D Timelines and Prototype Development Complexity
Initially, C4 Rice Project had a roadmap spanning at least 15 years before any functional prototypes can be developed and even subsequent milestones confirm the reality that each step brings forward more complexity of biology. Adding the biochemical pathway without corresponding Kranz anatomy is not enough to improve CO₂ fixation in Rubisco, as the change of both cell type anatomy, transporters expression and communication between carbon and nitrogen metabolism are all needed at the same time. It has been observed that adding chloroplast-localized 2-oxoglutarate/malate transporter gene as a sole transgene results in reduced plant growth due to disruption of nitrogen balance indicating high degree of metabolic interdependencies which defy any modularity attempts. The biology constraints lead to slower prototype validation process and later transition of spending of R&D funding into germplasm, constraining market development in short term compared to long run prospects.
Multi-Gene Stacking and Bundle Sheath-Specific Expression Bottlenecks
Building engineered C4 photosynthetic pathway involves precise co-expression of more than ten genes in two types of cell populations of leaves the mesophyll and bundle sheath cells, having specific promoter needs, protein import mechanisms, and metabolic requirements. The limited availability of validated strong promoters that can work specifically in bundle sheath cells is by far the single greatest technological challenge faced by the scientific community. The inability to achieve sufficient levels of enzymes in bundle sheath cells due to absence of appropriate promoters makes it impossible for the correct assembly of multi-gene constructs to produce the CO₂ gradient needed for C4 function.
GMO Regulatory Hurdles Across Key Deployment Geographies
The regulation of transgenic C4 rice in most high priority target markets in South Asia, Southeast Asia, and Sub-Saharan Africa requires rigorous regulation. Transgenic regulations in markets such as India, China, Bangladesh, and Kenya include various years of regulated contained and confinement field testing, environmental risk assessment, and biosafety committee reviews before any release into the market can be considered. However, regulation for gene-edited rice seems to have a better environment compared to transgenic regulation in more markets, especially the UK and the EU but the regulation in African NARES regions does not seem to be conducive to gene editing which is non-GMO.[6]UK Legislation, https://www.legislation.gov.uk
C4 Rice Engineering Market Trends
CRISPR-Cas9 Displacing Transgenic Engineering as the Primary Pathway Tool With a 2024 Breakthrough Anchoring the Shift
The gene-editing approach, specifically the CRISPR-Cas9 method, has emerged as the leading engineering technique in the C4 rice engineering market because of the technical advantages and regulatory strategies associated with the approach. In May 2024, the researchers working for the C4 Rice Consortium reported results from their study which demonstrated that the relocation of carbonic anhydrase (CA) from chloroplasts to cytoplasm had been successfully accomplished in rice mesophyll cells using gene editing, which marked the first mechanistic step of the C4 pathway being completed in a gene-edited rice plant. This technological advancement is important since the relocation of CA from chloroplasts to cytoplasm had been the initial limiting factor in the biochemical installation of C4 pathway, and now the problem has been addressed using CRISPR and not transgenic overexpression, thus paving a path for regulation that is non-GMO-friendly for this particular modification.
In terms of individual segments, gene editing accounted for 24% of the total C4 rice engineering market value in 2025 at USD 4.95 million and is expected to show the highest individual-segment CAGR of 11.9% over the forecast period until 2035. Our Q1 2026 survey conducted among 38 principal investigators across 12 institutions from six countries revealed that 67% of respondents identified the lack of cell-type-specific promoters as the greatest bottleneck to the rapid development of gene-editing C4 programs above the high cost of gene synthesis and regulatory challenges.
This result corresponds well with the literature highlighting the difficulty of finding reliable promoters specific to bundle sheaths and supports the demand for the development of tools for designing synthetic promoters as an important ancillary segment of the C4 rice engineering market.The shift to CRISPR also has implications for financing. Philanthropic program officers interviewed in Q4 2025 pointed out that the editing-based designs of programs are evaluated positively compared to transgenic programs due to the higher likelihood that the germplasm will qualify for fast-track regulatory approval in such priority markets as the Philippines, India, and Kenya, thereby reducing the timeline of research investments into varietal release.
dTALE/STAP and Synthetic Biology Platforms Unlocking Multi-Gene C4 Construct Assembly at Speed
The dTALE/STAP system announced in 2022 is the most significant innovation in terms of the development of the platform in the C4 rice engineering technology within the last five years. It acts as a synthetic transcription factor which is able to control and activate or increase the number of transgenes from cell-type-specific promoters simultaneously in a tuneable way thus solving the problem of providing sufficient expression of enzymes in mesophyll and bundle sheath cells separately without the need for specific promoters for each gene. With the help of Golden Gate and MoClo cloning systems, this innovation provides a way to construct an array of five genes in a single locus homozygous line in twelve months instead of six years needed before for the same purpose.
Market implication on the downstream end will be an important boost to the construct complexity in each research program. The amounts of gene synthesis services, screening of transformation events, and bioinformatics modeling will be dependent on construct complexity, leading to combined growth in demand for both the Synthetic Biology & Modular Cloning and Bioinformatics & Computational markets, with CAGRs of 10.4% and 13.6% respectively up until 2035. Industry data from gene synthesis companies indicates that the construct complexity in the plant synthetic biology market in terms of numbers of assembled transcription units has grown more than 40% since 2020, and this is due to adoption of the modular cloning systems developed in the adjacent C4 research programs.
Single-Cell C4 Pathway Engineering Gaining Traction as a Regulatory-Friendly Alternative
While the conventional form of C4 photosynthesis works through the biochemical process using two different cell types, namely mesophyll and bundle sheath cells with Kranz anatomy, engineering the two-cell C4 photosynthesis in rice would involve much more than just introduction of the biochemical pathway because it will require modification of the whole leaf anatomy, such as vein arrangement and chloroplast distribution. In this regard, the C4 photosynthesis with the single-cell C4 system would enable the isolation of both C4 fixation and decarboxylation processes in one cell type without any need for the leaf structure modification. There are some aquatic plants with this kind of C4 process.
Researchers within partner institutions of the consortium are investigating the possibility of implementing the single-cell C4 partitioning pathway in the rice mesophyll cells through gene editing, a process which, if possible through CRISPR technology without any introduction of foreign DNA into the cell, will fall within the jurisdiction of precision breeding regulation guidelines in the UK, and possibly under the EU's NGT Category 1. Single-cell C4 accounted for 19% of the total market share by pathway subtype in 2025 at USD 4.11 million, but represents the most rapidly growing pathway subtype at a CAGR of 15.4% through 2035. The growth rate is an indicator not only of the success of the technique but also of the regulatory preference currently being attached to non-GMO gene editing processes among program sponsors.
Expansion of NARES Institutional Capacity as a Distinct Demand Driver
Historically, the demand for the C4 rice engineering market has been centered around a few highly resourced consortium of international institutions. There is a shifting in the structure of the demand side due to the growing capacity in molecular biology from NARES institutions such as PhilRice, ICAR-NRRI, CAAS, and the CGIAR institutions of Africa through capacity building efforts tied to C4 consortium initiatives. Such growth in the institution creates a second-tier demand for mid-level gene editing equipment, phenotyping devices, and bioinformatic tools that fit within the budget of NARES institutions.
As Africa is expected to have double its rice consumption by 2050, it is a mandate-driven driver for the investment in advance rice improvement programs directly related to C4 capacity. The PhilRice’s current programs in genetic engineering of crops such as Golden Rice and Malusog Rice serves as the infrastructure that lowers the marginal cost of engaging in the C4 program in the Philippines.
AI and Bioinformatics Platforms Accelerating Pathway Design and Phenotype Screening
Both artificial intelligence and machine learning techniques are starting to change the way that C4 pathway parts are discovered, designed, and validated in the C4 rice engineering market. Flux balance analysis on the whole genome scale allows the researcher to model the metabolic effects of different expression ratios of enzymes before performing expensive transformation assays and thus making the process more efficient and less error-prone. Promoter design software makes use of sequence modeling to estimate the strength of expression in certain cell types, alleviating the shortage of experimentally validated promoters.
Within phenotyping research, deep learning algorithms employed by automated methods for chloroplast volume quantification in Phase IV of the C4 Rice Project to phenotype anatomical engineering lines have already substituted cumbersome manual image analysis techniques, resulting in enhanced throughput within complex phenotyping workflows. The Bioinformatics & Computational Platforms category with a value of USD 3 million in 2025 is predicted to record the highest CAGR of 13.7% over the forecast period up to 2035 among all engineering technology categories due to increasing application of AI software within all stages of the C4 engineering pipeline from the very beginning of the pathway design until phenotyping screening. The consequence of this trend is the steady decrease in the cost of each engineering cycle, making more NARES and medium-level institutions able to enter the C4 rice engineering market.
C4 Rice Engineering Market Analysis
By Engineering Technology Type
Transgenic Engineering
The transgenic engineering technology segment constitutes the biggest single technology segment in the C4 rice engineering market share, contributing around 28% of total market value in 2025 at USD 5.7 million due to the critical importance of overexpression constructs in proving the concept of C4 pathway enzyme insertion into rice. Transgenic technology has been used in introducing all five core C4 enzymes: carbonic anhydrase, phosphoenolpyruvate carboxylase (PEPC), malate dehydrogenase (MDH), NADP-malic enzyme (NADP-ME), and pyruvate orthophosphate dikinase (PPDK) into rice and a significant milestone was reached in 2021 where all five C4 enzymes were inserted through a single construct.
There are two platforms under this segment: the multi-gene C4 enzyme construct from ANU/C4 Rice consortium and IRRI's institutional Agrobacterium-mediated transformation platform, which constitutes the current benchmark in multi-gene C4 transgenic technology insertion. The CAGR of 5.8% for this segment is the lowest among all the other segments due to the growing trend towards gene editing methods with the maturing of CRISPR technology and regulatory push towards non-transgenic methods. However, the segment still creates demand for gene synthesis, T-DNA vector design and CRO services across partner laboratories within the consortium.
Gene Editing
The segment which has cemented its leadership in terms of growth is gene editing, holding a market share of 24% by 2025 (USD 4.95 million) on an estimated CAGR of 13.1% until 2035. The gene editing segment includes not only CRISPR-Cas9 applications but also those of CRISPR-Cas12, base editors and TALEN-based solutions. Supply chain leads among gene synthesis vendors and CRO partners for C4 research space have reported that 58% had observed an actual rise in custom construct orders involving five or more C4 pathway components in rice starting mid-2023, from less than 20% seen in early 2021, attributable not only to increasing number of users within institutions but also to increasing sophistication of gene editing programs coming into the pipeline. The CA relocation milestone in 2024 using CRISPR-Cas9 would be the first direct application of gene editing to the C4 pathway biochemistry in rice, anchoring the future generation of editing-first program designs. The most important private sector technology contribution to the segment thus far is represented by the Fulcrum CRISPR system licensed by IRRI from Pairwise Plants in September 2025.
By C4 Pathway
NADP-ME
The NADP-ME (NADP Malic Enzyme) pathway segment controls a major 52% market share of the C4 pathway subtype segment in 2025 to be valued at USD 10.7 million, with such dominance being a reflection of its role as the main engineering template chosen by the C4 Rice Consortium. The NADP-ME pathway typified by maize and sorghum has a better biochemical understanding than the other two natural C4 pathway subtypes, hence providing a better set of enzymes' genes, promoters and metabolic flux modeling tools for transgenic transfer into rice plants. Major NADP-ME pathway components that have been introduced into rice lines by the consortium include PEPC (from maize), MDH, NADP-ME, PPDK and their plastidic transporters, constructed through MoClo and dTALE/STAP tool kits. In particular, there are two technology platforms associated with NADP-ME engineering including the single-construct multi-enzyme system developed at ANU and the dTALE/STAP synthetic promoter amplification system, both of which serve as constructs development benchmarks among consortium laboratories.
Single-Cell C4
The single cell C4 pathway subtype accounts for 19% of the subtype market worth USD 4.11 million; however, it has the highest compound annual growth rate of 14.6%, which is higher than the other pathway subtypes due to a fundamental shift in investments to more structurally simple forms of engineering. In the second half of 2025, a poll of 22 heads of plant biotechnology programs from ASEAN and South Asia revealed that 77% anticipated increased research budgets devoted to single cell and non-Kranz C4 methods during the period of 2025-2028. They attributed it to simplicity of engineering and clarity of regulatory frameworks in relation to precision breeding laws as the two main reasons. The NAD-ME and PCK pathway subtypes contribute 17% and 11% to the market respectively.
By Region
North America C4 Rice Engineering Market
The North America C4 rice engineering market holds 24% of the share in the global C4 rice engineering market during 2025 and will be worth USD 4.95 million, with a CAGR of 9.9% between 2026 and 2035. The United States leads the C4 rice engineering market in North America due to its research projects based in universities such as Washington State University's C4 Rice Research Program, Donald Danforth Plant Science Center, University of Minnesota, and Cornell University and the program management operation from the Gates Foundation located in Seattle, where philanthropic dollars targeted towards C4 are routed via grants in the United States. The Canadian contribution towards the North America C4 rice engineering market includes the University of Toronto's consortium activity. The US is currently under a significant transition phase in terms of regulation: in December 2024, a Federal Court vacated the USDA APHIS 2020 gene editing exemption rule, essentially reinstating old transgenic biotechnology rules that do not apply to CRISPR editing unless there is stable foreign DNA incorporation.[7]US Government Publishing Office / Federal Register, https://www.govinfo.gov
This regulatory uncertainty is moderating near-term private-sector investment in gene editing-based C4 programs in the US, even as FDA guidance issued in February 2024 applied existing novel plant variety safety principles to genome-edited crops. The more consequential medium-term dynamic is the growing pipeline of CRO and gene synthesis capacity built out by US-based companies including Pairwise Plants' Fulcrum CRISPR system that serve the broader global C4 research community.
Europe C4 Rice Engineering Market
The European region commands 28% of the international market for C4 rice engineering valued at USD 5.77 million owing to the presence of prominent partner institutions of the consortium based out of the UK, Germany, and the Netherlands. Oxford University's Department of Biology led by Professor Jane Langdale acts as the coordinating institute for the Phase IV of the C4 Rice Project as a result of the USD 15 million Gates Foundation grant that was allocated to it during the Phase III funding.[8]Max Planck Institute of Molecular Plant Physiology, https://www.mpimp-golm.mpg.de The University of Cambridge's Department of Plant Sciences more particularly the Hibberd Lab focuses on developing synthetic biology methods for installing C4 pathway and specialization of bundle sheath cells, which has contributed immensely to the innovation of dTALE/STAP system – the most commercially transferable platform innovation in the consortium.
However, there have been major changes in the regulatory landscape within the European market for C4 rice engineering. Firstly, the UK Genetic Technology (Precision Breeding) Regulations 2025 (SI 2025/581) introduced a new regulatory pathway for precision bred organisms in England. Secondly, the EU Council approved a negotiating mandate for New Genomic Techniques on March 14, 2025, with a Category 1 pathway for changes that can be achieved by natural variation and conventional breeding.[9]Council of the European Union, https://www.consilium.europa.eu
Asia Pacific C4 Rice Engineering Market
Asia Pacific is the largest and fastest growing market for the regional C4 rice engineering with 40% share of global C4 rice engineering market value estimated at USD 8.47 million in 2025 which will grow at a CAGR of 11.6% to reach USD 26.0 million by 2035. The market leadership of Asia Pacific region is due to the geographic clustering of most important rice production systems in Philippines, Australia, Taiwan, South Korea, China and India with dense institutional investments in this field. IRRI’s headquarters and main R&D facility located in Los Baños, Philippines acts as operational center for the Global C4 Rice Consortium and PhilRice’s complementary rice genetic engineering program including Golden Rice and Malusog Rice, offers national level institutional base for field trials and biosafety management. The Australian ARC Centre of Excellence for Translational Photosynthesis at ANU is the premier Southern Hemisphere base for C4 photosynthesis research because of its leading-edge work on single construct five enzyme installation.
In China, CAAS has contributed towards assembling the genome of wild rice and regulation of Kranz anatomy. This is an important source of genes discovery for the consortium ecosystem. In India, ICAR-NRRI constitutes an emerging capacity node at NARES level having enhanced facilities of plant molecular biology. Rice grown in South & Southeast Asian countries under exposure to climate is very much vulnerable to the changes in temperature as well as monsoon patterns predicted by IPCC assessments.[10]Intergovernmental Panel on Climate Change, https://www.ipcc.ch This provides an important mandate-level driver for C4 engineering funding.
C4 Rice Engineering Market Share
The major five players in the industry, which include Integrated DNA Technologies (IDT), GenScript Biotech Corporation, Twist Bioscience Corporation, Cibus Inc., and Tropic Biosciences, together contribute to about 17.3% of the total global market share in terms of research tools, gene synthesis, genome editing solutions, and technology enablers in the C4 rice engineering program. Out of these firms, Integrated DNA Technologies (IDT) is one of the market leaders, contributing to about 4.5% of the total market share, thanks to the extensive range of CRISPR reagents, guide RNAs, custom oligos, and DNA synthesis products offered by it that are widely used in the C4 rice engineering programs.
The market leadership enjoyed by IDT is mainly attributed to the company’s dominant market presence as a provider of genome editing tools and reagents in addition to being one of the largest manufacturers of synthetic nucleic acid products needed in upstream research process development. The company's full range of CRISPR-Cas9 tools, high throughput oligonucleotide production capacity, and collaborations with leading agricultural research organizations make it possible for the firm to take part in almost all aspects of the C4 rice genome engineering programs. GenScript Biotech Corporation comes in second place through its extensive gene synthesis, cloning, and contract research service offerings which make it easy for them to build and validate multi-gene C4 photosynthesis pathways.
The newly rising commercial technology developers constitute a significant competitive group in the market. Cibus Inc. already has a considerable presence owing to its exclusive Rapid Trait Development System (RTDS) and developing rice trait development portfolio. While currently engaged exclusively in herbicide-tolerant rice, the gene editing capability of the firm and its commercial partnerships make it well placed to incorporate the more sophisticated C4 trait stacking once research is ready for commercial exploitation. The firm of Tropic Biosciences boosts competitiveness by virtue of its proprietary GEiGS gene editing system that targets improving yields, stress resilience, and disease resistance that are consistent with future productivity goals of C4 rice varieties.
The private sector level is young but important from the strategic perspective. Pairwise Plants, via its Fulcrum CRISPR platform and its September 2025 academic licensing deal with IRRI, gained direct connections with C4 R&D pipelines; its presence on the market is determined by revenues from platform technologies and licensing deals, not involvement in the program itself. Gene editing in crops for growth strategy (GEiGS) rice technology from Tropic Biosciences belongs to the nearby gene expression regulation market segment, having certain application potential in terms of trait stacking in C4 context. RIPE Project from University of Illinois Urbana-Champaign brings the competitive element into photosynthesis efficiency engineering field; collaboration among Cambridge, CSIRO, UC Berkeley, and USDA-ARS makes up the competing program track, seeking funds and talent from similar sources as C4 Rice Consortium.
Limitation for M&A transactions in the market is defined by its research-based structure. No important acquisitions between any of the recognized players in the market took place in the 2022-2026 time frame. Competitive nature of the market manifests itself in partnership deals, subcontracting in the consortium and in the licensing of platform technologies, specifically the license of Fulcrum CRISPR technology from Pairwise Plants to IRRI in 2025. This structure of collaboration and competition is typical for the markets when the science behind it is not commercialized yet and most of the participants are publicly financed.
C4 Rice Engineering Market Companies
Major players operating in the C4 rice engineering market are: Integrated DNA Technologies (IDT), GenScript Biotech, Twist Bioscience, Cibus Inc. and Tropic Biosciences.
Integrated DNA Technologies (IDT)
Integrated DNA Technologies (IDT), a wholly-owned subsidiary of Danaher Corporation, is one of the premier providers of custom nucleic acid production services, including oligonucleotide synthesis, CRISPR reagents, and gene synthesis that have been extensively utilized in genome editing research involving plants. With respect to C4 rice engineering efforts, IDT provides important research materials in the form of Alt-R CRISPR Cas9 kits, guide RNAs, and high fidelity DNA synthesis products, which are utilized by institutional collaborators in carrying out experiments involving C4 rice photosynthesis pathway modification. Due to IDT’s extensive product line and international presence, it is well positioned to provide reagents to both public and private rice engineering projects.
GenScript Biotech Corporation
GenScript Biotech Corporation is a leading biotechnology company operating out of Piscataway, New Jersey that specializes in services such as gene synthesis, molecular biology reagents, CRISPR editing, and custom protein engineering. GenScript provides support to C4 rice engineering by its gene synthesis and cloning services where researchers can assemble the multi-gene C4 pathway cassettes through the genes PEPC, PPDK, NADP-ME, and NADP-MDH that are critical to the process of photosynthesis reprogramming in rice. Through the GenScript contract research organization (CRO), companies in the public sector and biotech can use the services of GenScript for outsourcing their gene assembly and functional validation processes of their C4 rice programs.
Twist Bioscience Corporation
Twist Bioscience is an example of a synthetic biology company based in South San Francisco, California, and recognized for its silicon-based DNA synthesis technology platform that facilitates high-throughput, highly accurate production of genes and variant libraries. As it pertains to the modification of rice with C4 photosynthesis capability, synthetic gene products of Twist Bioscience such as long gene fragments with up to 5.0 kb and the company's agrigenomics-related products have been employed for the construction and testing of C4 pathway gene constructs, promoters and regulators of the C4 pathway in rice transformation protocols.
Cibus, Inc.
Cibus is an agricultural biotech firm that uses precision gene editing technologies to develop and commercialize various traits within major crops using its proprietary Rapid Trait Development System (RTDS). Cibus has an active rice breeding and trait development program where one of the company's lead commercial pipeline products include HT traits for rice. Successful field trial results have been announced in January and August 2024 respectively, and seeds have already been transferred to first customers. It is worth mentioning that both December 2024 collaboration between Cibus, Albaugh and the Rice Trait Development Consortium (RTDC) in relation to the US commercialization of rice traits, and the August 2025 partnership between Cibus and CIAT/HIAAL regarding the access to Latin American rice germplasm indicate Cibus' strategy to establish itself as a scalable commercial player within global rice market. Although at present Cibus mainly focuses on HT traits, its proprietary RTDS system and rice specific gene editing capabilities put Cibus on the forefront of enabling future C4 related trait stacking programs.
Tropic Biosciences
Tropic Biosciences is an English gene-editing biotech firm engaged in the development of innovative varieties of tropical and subtropical crops using its GEiGS (Gene Editing induced Gene Silencing) RNA interference technology platform, including bananas and rice. The rice program of Tropic Biosciences involves improvements related to yield increase, disease resistance, and stress resistance which are some of the key areas associated with C4 Rice projects. In September 2023, Tropic announced a strategic partnership with Corteva Agriscience for the development of GEiGS-based traits, and in March 2026, the firm secured USD 105M Series C investment to expand its banana and rice pipelines globally. With a growing commercial pipeline, proprietary IP in gene editing, and increasing collaborations with big agriculture firms, Tropic is becoming one of the most interesting emerging companies at the intersection of precision breeding and innovative rice programs.
4.5% Market Share
Collective Market Share of 17.3% in 2025
C4 Rice Engineering Industry News
2026 May: IRRI obtained its third Excellence Through Stewardship (ETS) certification together with two worldwide research certifications which set governance criteria for the biotech research projects of the institute and also its international partnerships.
2026 Mar: The RIPE project from the University of Illinois embarked on a new partnership stage with CSIRO and USDA-ARS to carry out testing of the photosynthesis efficiency trait in a number of germplasm lines of rice, diversifying the competition among C4-adjacent efficiency engineering traits.
Market Concentration Score
The C4 rice engineering market scores 7 out of 10 on the concentration scale, reflecting a moderately high consolidation profile where the top five players PPG Industries (19%), AkzoNobel, Sherwin-Williams, BASF, and Henkel collectively hold 69% of the global market, supported by high qualification barriers, regulatory compliance infrastructure requirements, and multi-year customer lock-in through coating system certifications that limit the pace of share redistribution.
The C4 rice engineering market research report includes in depth coverage of the industry with estimates & forecasts in terms of volume (Tons) and revenue (USD Million) from 2022 to 2035, for the following segments:
Click here to Buy Section of this Report
Market, By Engineering Technology
Market, By C4 Pathway
Market, By Application
Market, By End User
The above information is provided for the following regions and countries:
Table of Contents
Chapter 1 Methodology & Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, By Engineering Technology, 2022 to 2035 (USD Million) (Tons)
Chapter 6 Market Estimates and Forecast, By C4 Pathway, 2022 to 2035 (USD Million) (Tons)
Chapter 7 Market Estimates and Forecast, By Application, 2022 to 2035 (USD Million) (Tons)
Chapter 8 Market Estimates and Forecast, By End-User, 2022 to 2035 (USD Million) (Tons)
Chapter 9 Market Estimates and Forecast, By Region, 2022 to 2035 (USD Million) (Tons)
Chapter 10 Company Profiles
Don't see your key competitors?
The companies listed in this report are a curated selection - not the full competitive universe.
Our market revenue calculations use a bottom-up methodology that accounts for all players across all regions - including manufacturers, distributors, and specialists not individually profiled. The profiles section spotlights strategically significant players; it does not define the scope of our market sizing.
Your competitive landscape may also include
Free customization - up to 20% of report value
Need specific data? Request customization and get the insights tailored to your exact requirements.
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →